about
Role of biologics in severe eosinophilic asthma - focus on reslizumabClimate Change and Air Pollution: Effects on Respiratory AllergyFractional exhaled nitric oxide-measuring devices: technology update.Effects on asthma and respiratory allergy of Climate change and air pollutionPharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPDSirtuin 1 and aging theory for chronic obstructive pulmonary diseaseSmall cell lung cancer associated with solitary fibrous tumors of the pleura: a case study and literature reviewUpdate on anticytokine treatment for asthmaAsthma-related deathsTreating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a reviewThunderstorm-related asthma: what happens and why.Application of proteomics and peptidomics to COPD.Molecular mechanisms of corticosteroid actions in chronic inflammatory airway diseases.Update on optimal use of omalizumab in management of asthma.ISSQoL: a new questionnaire for evaluating the quality of life of people living with HIV in the HAART era.Biological targets for therapeutic interventions in COPD: clinical potentialMolecular mechanisms underlying airway smooth muscle contraction and proliferation: implications for asthma.Recurrent respiratory infections caused by a double aortic arch: The diagnostic role of spirometry.The potential of biologics for the treatment of asthma.Bone and soft tissue non-Hodgkin lymphoma of the maxillofacial area: report of two cases, literature review and new therapeutic strategies.Neuroendocrine differentiation in breast carcinoma with osteoclast-like giant cells. Report of a case and review of the literature.Dupilumab: a novel treatment for asthma.Anti-IgE therapy with omalizumab for severe asthma: current concepts and potential developments.Cellular mechanisms underlying eosinophilic and neutrophilic airway inflammation in asthma.Pharmacological basis and scientific rationale underlying the targeted use of inhaled corticosteroid/long-acting β2-adrenergic agonist combinations in chronic obstructive pulmonary disease treatment.Surgical management of cervico-mediastinal goiters: Our experience and review of the literature.Long-term treatment in pediatric asthma: an update on chemical pharmacotherapy.Cushing's like syndrome in typical bronchial carcinoid a case report and review of the literature.Abdominal adiposity is an early marker of pulmonary function impairment: Findings from a Mediterranean Italian female cohort.Molecular and cellular mechanisms underlying the therapeutic effects of budesonide in asthma.Effects of statins and farnesyl transferase inhibitors on ERK phosphorylation, apoptosis and cell viability in non-small lung cancer cells.Comparison of the bronchodilating effects of inhaled formoterol, salmeterol and salbutamol in asthmatic patients.Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - EIP on AHA Twinning Reference Site (GARD research demonstration project).The diagnostic accuracy of fine-needle cytology of Hurthle cell lesions; A comprehensive cytological, clinical and ultrasonographic experience.Induced sputum as a tool for early detection of airway inflammation in connective diseases-related lung involvement.Surgical approach in thymectomy: Our experience and review of the literature.Age as a risk factor in the occurrence of pneumothorax after transthoracic fine needle biopsy: our experience.Impact of long-term treatment with inhaled corticosteroids and bronchodilators on lung function in a patient with post-infectious bronchiolitis obliterans.T cell activation state in the induced sputum of asthmatics treated with budesonide.Non respiratory symptoms in asthma as possible predictors of exacerbations.
P50
Q26738503-C8737E6F-EA04-4A5A-979A-A596C8F944C9Q26743372-1BF9584E-E5BF-46AE-87C3-DAACBE29D851Q26744314-7C4C6746-5FF4-4DF9-9DEB-23F201D2CF22Q26772280-BB3EEE0B-612B-4D40-BA8F-5DCE5FA04CF1Q26778685-EA8F8057-3A6C-49AA-875B-7F7888277987Q26799889-0F7BAEF5-46AD-4697-8BD2-DDEB7A3268E1Q27011422-C9ECC44C-BB9B-44FC-8871-0EBF374111BBQ27013617-50642E32-3909-461C-AAFE-25698D207E79Q28073233-FDBACF13-D8AE-4684-8DCC-FB04C3B6F2B7Q30801642-BE6FA35D-31EC-4C6D-96E5-8CC172B5001FQ31036827-42E1D8EF-97A7-4444-A4AC-AB29D666E34EQ33634488-21F1B0C3-A4E3-4B8D-978D-2D5BB2047454Q35054431-A68477D8-AC4F-45E8-90A7-6ADE0FE02E4CQ35117827-B511B671-98D6-4406-B5F2-D94BC5078CCFQ36425584-CF427E9C-FFBB-4B74-BB65-986AF530AB0CQ37018843-3950EF6A-17EB-4942-AD30-E2C68DD41957Q37200017-3D210081-693E-40C7-8F3A-32ACA170643AQ37576429-95163E88-0273-4500-8B60-054E1865FAB7Q38063791-C3C79C01-89ED-4A73-902D-DF6F629BCC69Q38243563-4B769FF9-5C1C-4047-AE90-162015357D24Q38247506-88C62139-77A0-417A-B51E-EC563B2074A5Q38248590-56EA74CB-97A4-4361-9500-FDB1A9A5F2CEQ38293927-BCD6268A-13AC-4012-A593-0D0F8B38177AQ38423076-FF989305-8EE6-422D-A22F-0A842C89B812Q38550921-8782CB20-75D8-4FA1-A074-789E13132D0CQ38684219-916D22F1-3816-4056-ACF3-89B97B27FCDBQ38733745-766EF00F-776A-42F4-BFEC-A13A03B911FFQ38753638-454C3975-FDEE-4F9E-AF83-4B29DFA8C58AQ38876968-1EFE79A0-0C05-4823-B8A3-6D6B89FE2B61Q38887287-5D8E4EF4-1F88-4D02-B840-7B8571951696Q39263831-641628BF-FB1D-4CDE-B8C8-9C8E8D5B69F3Q39401580-A8D8D1AB-B338-4FBB-B684-A3B85BF68882Q40165178-FC6F4B90-3950-484D-874E-84E75EEFA7A8Q40167023-8F76B07E-1A31-4DFF-AAD5-B29CF2CBB3E3Q40232466-C69EB916-6597-49C4-908A-4939375A2BCFQ41272378-8F96A2AD-260A-491A-9AAD-49A248A4B5E9Q41757909-69F50980-BDC6-435E-A168-DDA2FBB3C686Q42357078-EB03D92B-D051-484A-8D84-EFD4E27BAE0CQ42860271-7B0CF6C6-EF3B-44C2-B2E0-517E695AA02EQ43333595-CB67BDD6-9633-4E0A-85F4-34B0481E07AB
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alessandro Vatrella
@ast
Alessandro Vatrella
@en
Alessandro Vatrella
@es
Alessandro Vatrella
@nl
Alessandro Vatrella
@sl
type
label
Alessandro Vatrella
@ast
Alessandro Vatrella
@en
Alessandro Vatrella
@es
Alessandro Vatrella
@nl
Alessandro Vatrella
@sl
prefLabel
Alessandro Vatrella
@ast
Alessandro Vatrella
@en
Alessandro Vatrella
@es
Alessandro Vatrella
@nl
Alessandro Vatrella
@sl
P1053
K-8001-2016
P106
P1153
6701595368
P21
P31
P3829
P496
0000-0001-8265-3037
P569
2000-01-01T00:00:00Z